La malaltia inflamat\u00f2ria intestinal compr\u00e8n un grup ampli i heterogeni de processos autoinflamatoris que provoquen una inflamaci\u00f3 cr\u00f2nica i recurrent del tracte gastrointestinal, com \u00e9s el cas de la colitis ulcerosa i la malaltia de Crohn. Tot i que s\u2019ha demostrat que la composici\u00f3 gen\u00e8tica individual, els factors ambientals i el sistema immunitari s\u00f3n actors clau en el desenvolupament d\u2019aquestes patologies, encara es desconeixen les seves causes concretes i els mecanismes moleculars que les desencadenen. De fet, estudis del genoma complet realitzats amb grans grups de pacients han revelat que m\u00e9s de 200 gens podrien estar implicats en el desenvolupament de la malaltia.<\/p>\n
Les estrat\u00e8gies terap\u00e8utiques m\u00e9s recents per a la malaltia inflamat\u00f2ria intestinal s\u2019han centrat en l\u2019\u00fas de mol\u00e8cules destinades a modular o a inhibir components concrets de les reaccions dels processos immunoinflamatoris, com les interleucines. No obstant aix\u00f2, aquestes mol\u00e8cules encara no han complert les expectatives pel que fa a l’efic\u00e0cia i la seguretat, donant lloc a un percentatge important de pacients que no hi responen de forma satisfact\u00f2ria.<\/p>\n
El grup de recerca en processos immunoinflamatoris de l\u2019IDIBELL, liderat per l\u2019investigador Josep Maria Aran, ha treballat en el desenvolupament d\u2019un f\u00e0rmac biol\u00f2gic derivat d\u2019una prote\u00efna que es troba a la circulaci\u00f3 sangu\u00ednia, amb una forta activitat immunomoduladora. I ha demostrat que \u00e9s capa\u00e7 de reprogramar les c\u00e8l\u00b7lules immunit\u00e0ries i resoldre els processos immuno-inflamatoris amb gran efic\u00e0cia i sense efectes secundaris. La seva recerca, realitzada amb finan\u00e7ament CaixaReseach Validate<\/em> de la Fundaci\u00f3 \u201cla Caixa\u201d i amb la participaci\u00f3 de professionals del servei de Gastroenterologia de l’Hospital Universitari de Bellvitge, resol que aquesta prote\u00efna restableix l\u2019home\u00f2stasi del sistema immune i que, en conseq\u00fc\u00e8ncia, t\u00e9 un gran potencial per al tractament de multitud de malalties autoimmunes i autoinflamat\u00f2ries.<\/p>\n En concret, l\u2019estudi, publicat a la revista Pharmacological Research<\/em>, descriu de manera detallada el mecanisme d’acci\u00f3 \u00fanic de la prote\u00efna C4BP (\u03b2-), i posa en valor el seu potencial terap\u00e8utic per al tractament de la malaltia inflamat\u00f2ria intestinal, molt prevalent en la poblaci\u00f3. Tot utilitzant models animals de la malaltia, l\u2019article demostra que C4BP (\u03b2-) confereix un fenotip antiinflamatori i immunomodulador robust, ja que atenua significativament els trets histopatol\u00f2gics (com la infiltraci\u00f3 de c\u00e8l\u00b7lules immunit\u00e0ries inflamat\u00f2ries al c\u00f2lon de ratolins que reprodueixen la malaltia humana) i preserva la integritat de l\u2019epiteli intestinal amb abs\u00e8ncia d’efectes no desitjats. Al seu torn, la prote\u00efna PRP6-HO7, un an\u00e0leg m\u00e9s petit i amb nom\u00e9s activitat immunomoduladora, va aconseguir un resultat similar al de la prote\u00efna C4BP (\u03b2-).<\/p>\n En conjunt, els resultats del grup del Dr. Aran apunten que l\u2019\u00fas de C4BP (\u03b2-) i, m\u00e9s concretament, de la seva versi\u00f3 millorada PRP6-HO7, podria constituir una opci\u00f3 terap\u00e8utica prometedora per a la malaltia inflamat\u00f2ria intestinal, tal com ja han demostrat en experiments amb c\u00e8l\u00b7lules humanes derivades de pacients de colitis ulcerosa.<\/p>\n <\/p>\n <\/p>\n L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" El grup de recerca en processos immunoinflamatoris de l\u2019IDIBELL demostra que la prote\u00efna C4BP (\u03b2-) podria constituir una opci\u00f3 terap\u00e8utica prometedora per a la malaltia inflamat\u00f2ria intestinal.<\/p>\n","protected":false},"author":8,"featured_media":24374,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[334,464,378],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-24 11:30:14","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24373"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=24373"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24373\/revisions"}],"predecessor-version":[{"id":24375,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24373\/revisions\/24375"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/24374"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=24373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=24373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=24373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}